fda warning letters compounded semaglutide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Issues 30 Warning Letters

Slows digestion Keeps food in your stomach longer, keeping you fuller between meals

Plaintiffs legal claims state that Hims statements about its Wegovy offerings and partnerships were materially false and misleading, lacking a reasonable basis, and harmed investors

[DOI] [PubMed] [Google Scholar] 98.Yaribeygi H., Sathyapalan T., Atkin S.L., Sahebkar A

Second Natures published outcomes data shows members on our GLP-1 programmes lose an average of 19.1% of their starting body weight at 12 months, with 77.7% achieving a clinically meaningful loss of 10% or more

Triple agonist therapy essentially gives them unlimited energy, clear instructions, and better materials